Clinical TrialJul 17, 2026, 04:16 PM
Zentalis to present overall survival data for azenosertib at ESMO
AI Summary
Zentalis Pharmaceuticals announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026. The company will deliver a rapid oral presentation on overall survival data from the DENALI Part 1b study of azenosertib, highlighting long-term survival benefits in Cyclin E1-positive platinum-resistant ovarian cancer. Additionally, a trial-in-progress poster will detail the ASPENOVA Phase 3 study, which aims to support full approval of azenosertib monotherapy in this biomarker-selected patient population.
Key Highlights
- Zentalis to present overall survival data from DENALI Part 1b study of azenosertib.
- Rapid oral presentation scheduled for October 23, 2026, at ESMO Congress 2026.
- Data highlights long-term survival benefits in Cyclin E1-positive platinum-resistant ovarian cancer.
- Trial-in-progress poster for ASPENOVA, a Phase 3 study of azenosertib monotherapy.
- ASPENOVA trial to enroll approximately 420 patients with Cyclin E1-positive PROC.
- Azenosertib is an investigational, first-in-class WEE1 inhibitor for ovarian cancer.
Price Impact
More from ZNTL